Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Current Diabetes Reports

• Publication date

  2019-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11892-019-1266-7PMID 31748838
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.

  2019cited by this paper
• Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis

  2019cited by this paper
• Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

  2019cited by this paper
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

  2019cited by this paper
• SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

  2019cited by this paper
• Stem cells from human exfoliated deciduous teeth ameliorate type II diabetic mellitus in Goto-Kakizaki rats

  2019cited by this paper
• Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study

  2019cited by this paper
• Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

  2018cited by this paper
• Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

  2018cited by this paper
• Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

  2018cited by this paper
• Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

  2018cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial

  2017cited by this paper
• Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

  2017cited by this paper
• Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.

  2017cited by this paper
• Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

  2017cited by this paper
• Clinical Perspective What Is New ?

  2017cited by this paper
• Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

  2017cited by this paper
• SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature

  2017cited by this paper
• Fracture risk associated with common medications used in treating type 2 diabetes mellitus.

  2017cited by this paper
• Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

  2017cited by this paper
• The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study

  2016cited by this paper
• Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study

  2016cited by this paper
• The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials

  2016cited by this paper
• Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

  2015cited by this paper
• Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors

  2015cited by this paper
• Cardiometabolic Effects of a New Class of Antidiabetic Agents.

  2015cited by this paper
• Canagliflozin-induced pancreatitis: a rare side effect of a new drug

  2015cited by this paper
• Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

  2015cited by this paper
• Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus

  2015cited by this paper
• Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.

  2015cited by this paper
• Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

  2015cited by this paper
• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

  2015cited by this paper
• Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

  2014cited by this paper
• Cardiovascular actions of incretin-based therapies.

  2014cited by this paper
• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

  2014cited by this paper
• Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials

  2014cited by this paper
• Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

  2013cited by this paper
• Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

  2013cited by this paper
• Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.

  2011cited by this paper
• Insulin detemir versus insulin glargine for type 2 diabetes mellitus.

  2011cited by this paper
• Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis

  2010cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

  2010cited by this paper
• Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

  2010cited by this paper
• The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

  2010cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

  2009cited by this paper
• Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

  2009cited by this paper
• Restaging insulin therapy for patients with type 2 diabetes

  2009cited by this paper
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

  2009cited by this paper
• Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis

  2009cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

  2007cited by this paper
• GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients

  2004cited by this paper
• The potential role of glucagon-like peptide 1 in diabetes.

  2004cited by this paper
• Regulation of adipocytokines and insulin resistance

  2003cited by this paper
• Acarbose for the prevention of diabetes.

  2003cited by this paper
• Insulin granule dynamics in pancreatic beta cells

  2003cited by this paper
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

  2002cited by this paper
• Pharmacological modulation of K(ATP) channels.

  2002cited by this paper
• PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth*

  2001cited by this paper
• PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth.

  2001cited by this paper
• Insulinotropic meglitinide analogues.

  2001cited by this paper
• Role of AMP-activated protein kinase in mechanism of metformin action.

  2001cited by this paper
• Optimisation of the Management of Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus

  2001cited by this paper
• Pharmacological modulation of KATP channels

  2001cited by this paper
• Long-Term Prevention of Bone Loss

  2000cited by this paper
• Meglitinide Analogues in the Treatment of Type 2 Diabetes Mellitus

  2000cited by this paper
• Closing the audit loop with the Diabetes Clinic Satisfaction Questionnaire (DCSQ) : reducing sources of dissatisfaction and increasing clinician sensitivity to patients' views

  1999cited by this paper
• Pharmacologic Therapy for Type 2 Diabetes Mellitus

  1999cited by this paper
• A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus

  1999cited by this paper
• ATP-sensitive K+ channels and insulin secretion: their role in health and disease

  1999cited by this paper
• Thiazolidinediones: a new class of antidiabetic drugs

  1999cited by this paper
• Metformin: A review of its metabolic effects

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Contraindications to Metformin Therapy in Patients With NIDDM

  1997cited by this paper
• Comparative Tolerability Profiles of Oral Antidiabetic Agents

  1994cited by this paper
• [Antidiabetic drugs].

  1979cited by this paper

• Effects of propolis supplementation on blood glucose and lipid profiles in individuals with metabolic syndrome and type 2 diabetes: a systematic review and meta-analysis

  2026cites this paper
• Use of second-line diabetes mellitus medications among older adults after the introduction of GLP-1 receptor agonists in Ontario, Canada: a retrospective cohort study.

  2025cites this paper
• Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus

  2025cites this paper
• The role of hyperglycaemia, oxidative stress, and inflammation in diabetes-related male infertility: Therapeutic properties of medicinal plants

  2025cites this paper
• Feasibility and Efficacy of a Plant-Based Nutrition Intervention for Type 2 Diabetes in a Primary Care Setting.

  2025cites this paper
• Piperonal-Derived (E)-2-(2-(Benzo[d][1,3]dioxol-5-ylmethylene)hydrazineyl)-4-(aryl)thiazole Derivatives as Potential Therapeutic Leads for Diabetes and Alzheimer's Disease: In Vitro and In Silico Evaluation Against α-Glucosidase, α-Amylase, Acetylcholinesterase, and Butyrylcholinesterase

  2025cites this paper
• Evaluating prediction of short‐term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population‐based study

  2025cites this paper
• Investigation of Crinum solapurense leaves extract for antidiabetic activity and histopathological evaluation in an in-vivo experimental model

  2025cites this paper
• Milk-derived bioactive peptides in insulin resistance and type 2 diabetes.

  2025cites this paper
• Effects of potentilla discolor bunge extracts on oxidative stress and glycolipid metabolism in animal models of diabetes: a systematic review and meta-analysis

  2023cites this paper
• Assessment of Antidiabetic and Anti-Inflammatory Activities of Carissa carandas Linn Extract: In Vitro and In Vivo Study

  2023cites this paper
• The Intervention of Probiotics on Type 2 Diabetes Mellitus in Animal Models.

  2023cites this paper
• Antioxidant, antimicrobial, α-amylase and α-glucosidase inhibitory activities of methanolic leaf extract of Breynia vitis-idaea using in vitro and in silico techniques

  2023cites this paper
• Integrated Chinese and Western Medicine for Coronary Heart Disease Prevention in Polycystic Ovary Syndrome: A 19-Year Nationwide Cohort Study

  2023cites this paper
• Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

  2022cites this paper
• Mulberry-Derived 1-Deoxynojirimycin Prevents Type 2 Diabetes Mellitus Progression via Modulation of Retinol-Binding Protein 4 and Haptoglobin

  2022cites this paper
• Completeness of pharmaceutical industry insulin adverse event reports from Africa and the Middle East

  2022cites this paper
• Evaluation of Anti-Diabetic and Anti-Hyperlipidemic Activities of Hydro-Alcoholic Crude Extract of the Shoot Tips of Crinum abyssinicum Hochst. ex A. Rich (Amaryllidaceae) in Mice

  2022cites this paper
• Individual Case Safety Reports Analysis for Patients with Diabetes Mellitus on Insulin in Africa and the Middle East.

  2021cites this paper
• Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

  2020cites this paper
• Ultrasound-Assisted Extraction Optimization of α-Glucosidase Inhibitors from Ceratophyllum demersum L. and Identification of Phytochemical Profiling by HPLC-QTOF-MS/MS

  2020cites this paper
• Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression—A Literature Review

  2020cites this paper
• SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

  2019cites this paper
• Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis

  2019cites this paper
• Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

  2017cites this paper